Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety period in pediatric epilepsy subjects age 2 to 5 years.

Phase 1/Phase 2

Neurelis, Inc.

Diazepam